A surgical drape surface treatment process that is antistatic and low-fuzz

Abstract

The application discloses a surface treatment process of an antistatic and low-fuzz surgical drape, and relates to the field of layered products.The treatment process comprises the following steps: S1, using a dielectric barrier discharge plasma to treat the surgical drape; S2, using a padding method or a spraying method to apply an antistatic agent solution; S3, uniformly spraying an end-capping agent solution on the surface of the drape treated in the step S2; and S4, steam sterilization, and obtaining the antistatic and low-fuzz surgical drape after cooling.The low-melting-point polymer is compounded with the water-soluble end-capping agent, and combined with high-pressure steam sterilization, so that the polymer can migrate to the end along the capillary effect of the fiber surface after contacting the surface of the drape, and the auxiliary film-forming agent can be instantaneously swelled when meeting water vapor, the polymer can be guided to wrap the fiber end breaking point, and the polymer can be solidified to form a microspherical mechanical lock after cooling.The physical wrapping mechanism of the application can more completely control the falling of the fuzz, so that the risk of foreign body reaction or infection of a surgical incision caused by the falling of the fuzz can be further reduced.

Description

Technical Field

[0001] This invention relates to the field of layered product technology, and in particular to a surface treatment process for surgical drapes that is antistatic and has low lint shedding. Background Technology

[0002] In the operating room environment, surgical drapes are the core consumables for constructing a sterile environment in the operating room. They are key barrier materials for isolating pathogenic microorganisms and maintaining the cleanliness of the surgical area. Currently, synthetic fiber drapes (such as polypropylene PP, polyethylene PE, and polyethylene terephthalate PET) are widely used in clinical practice. Due to their advantages such as high mechanical strength, good breathability, and controllable cost, they have gradually replaced traditional cotton materials.

[0003] However, the low surface energy of synthetic fibers makes them highly susceptible to static electricity buildup in dry operating room environments (where relative humidity is often below 40%) due to dynamic contact such as friction from medical staff handling and placement of instruments. This results in a high static voltage on the surface of the drape. This static electricity not only attracts dust particles, microbial spores, and surgical powder from the air, forming a potential source of contamination in the surgical area, but may also interfere with the signal stability of precision electronic devices such as electrosurgical units.

[0004] Meanwhile, during the repeated folding and instrument dragging of surgical drapes, the fiber ends are prone to breakage and shedding due to mechanical stress, forming micron-sized lint (mostly 5-100μm in diameter). If the lint falls onto the surface of the surgical wound, it may cause foreign body reaction, inflammatory reaction or postoperative infection, significantly increasing the risk of postoperative complications.

[0005] Therefore, it is necessary to improve upon the shortcomings of existing technologies in order to solve the above problems. Summary of the Invention

[0006] This invention overcomes the shortcomings of the prior art and provides a surface treatment process for surgical drapes that is antistatic and has low lint shedding.

[0007] To achieve the above objectives, the technical solution adopted by the present invention is: a surface treatment process for surgical drapes that is antistatic and has low lint shedding, comprising the following steps:

[0008] S1. Surgical drapes are treated with dielectric barrier discharge plasma.

[0009] S2. Apply an antistatic agent solution to the sheet treated in step S1 by padding or spraying, and react at 80~120 ℃ for 3~10 min.

[0010] S3. The capping agent solution is uniformly sprayed onto the surface of the sheet treated in step S2 by ultrasonic atomization spraying; the capping agent solution contains 3~8 wt% of low melting point polymer, 0.1~0.5 wt% of auxiliary film-forming agent and solvent;

[0011] S4. The fabric treated in step S3 is subjected to high-pressure steam sterilization at 117-125 ℃ to melt the low-melting-point polymer and migrate to the fiber ends. After cooling, an antistatic, low-lint surgical fabric is obtained.

[0012] In a preferred embodiment of the present invention, in step S3, the low-melting-point polymer is one of polyethylene glycol with a molecular weight of 1500-4000 Da or polycaprolactone with a molecular weight of 2000-5000 Da; the auxiliary film-forming agent is hydroxypropyl methylcellulose; and the solvent is a water / ethanol mixture with a volume ratio of 6-7:3-4.

[0013] In a preferred embodiment of the present invention, in step S3, the particle size of the atomized spray is controlled to be 5~20μm, and the spraying amount is 1~3 g / m². 2 An auxiliary wind speed of 0.5~1 m / s.

[0014] In a preferred embodiment of the present invention, in step S1, the processing gas for plasma treatment is argon or an argon / oxygen mixture, wherein the volume ratio of the argon / oxygen mixture is 90~95:5~10.

[0015] In a preferred embodiment of the present invention, in step S1, the plasma treatment power is 50~150W, the treatment time is 30~120 s, and the treatment distance is 5~20 mm.

[0016] In a preferred embodiment of the present invention, in step S2, the antistatic agent solution is an aqueous solution or an alcoholic aqueous solution of a permanent antistatic agent containing reactive groups, with a concentration of 5-15 wt%.

[0017] In a preferred embodiment of the present invention, the reactive group is one of epoxy group, isocyanate group or siloxane group; the permanent antistatic agent is selected from one of epoxy-modified polyether type antistatic agent, isocyanate-terminated polyether / polyester type antistatic prepolymer or organosiloxane containing quaternary ammonium salt group.

[0018] In a preferred embodiment of the present invention, in step S2, the padding method is one dip and one roll with a liquid yield of 70-90%; the spraying method has a pressure of 1-3 bar and a flow rate of 100-300 mL / min.

[0019] In a preferred embodiment of the present invention, in step S4, the pressure of the high-pressure steam sterilization is 0.1-0.2 MPa, and the time is 8-15 min.

[0020] This invention provides an antistatic, low-lint surgical drape, obtained by any of the aforementioned surface treatment processes.

[0021] This invention addresses the shortcomings of the prior art and has the following beneficial effects:

[0022] (1) This invention provides a surface treatment process for antistatic and low-lint surgical drapes. By compounding a water-soluble end-capping agent with a low-melting-point polymer and combining it with high-pressure steam sterilization, the mobility of low molecular weight PEG / PCL molecular chain segments is enhanced. After contacting the drape surface, they can migrate to the ends along the capillary action of the fiber surface. At the same time, the auxiliary film-forming agent swells instantaneously when it comes into contact with water vapor, guiding the polymer to wrap the fiber end breakage point. After cooling, the polymer solidifies to form microsphere mechanical locks, which can effectively eliminate the source of lint shedding. Compared with the traditional method of reducing lint shedding by increasing fiber twist or adding adhesives, the physical coating mechanism of this invention has a more thorough control over lint shedding, thereby further reducing the risk of foreign body reaction or infection caused by lint shedding in surgical wounds.

[0023] (2) In this invention, by activating the surgical drape with plasma beforehand, the fibers on the surface can generate active free radicals. After heating and reaction, they can covalently bond with the reactive groups on the applied reactive antistatic agent molecules, making them firmly anchored on the fiber surface, thereby forming an antistatic layer that is not easy to fall off, ensuring the durability of the antistatic effect, and overcoming the defect that traditional adsorption antistatic agents are easy to migrate and lose due to friction. Furthermore, it ensures that the drape can stably discharge static charge during use, thereby avoiding static electricity from interfering with the surgical environment and electronic equipment.

[0024] (3) The end-capping agent solution sprayed on the surface of the fabric in this invention has repeating ether bonds in its PEG molecular chain, which can form hydrogen bonds or van der Waals forces with the active free radicals on the fiber surface after plasma activation. The lone pair electrons enriched on the ether oxygen atom can undergo ion-dipole coupling with the cations of the antistatic layer, which broadens the charge dissipation channel. Furthermore, it can adsorb environmental moisture through its ether bonds, forming a dynamic hydration layer, which improves the dissipation rate of static charge. In addition, the hydrophilicity of PEG supplements the charge conduction path of the antistatic agent, and can maintain a low surface resistance even in a dry environment, thereby improving the performance stability of the fabric during folding and friction. Attached Figure Description

[0025] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0026] Figure 1 This is a flowchart of a surface treatment process for antistatic and low-lint surgical dressings according to a preferred embodiment of the present invention. Detailed Implementation

[0027] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0028] Many specific details are set forth in the following description in order to provide a full understanding of the invention. However, the invention may also be practiced in other ways different from those described herein. Therefore, the scope of protection of the invention is not limited to the specific embodiments disclosed below.

[0029] It should be noted that the raw materials, equipment and reagents used in this invention can all be purchased from the market or obtained through existing preparation methods.

[0030] like Figure 1 As shown, a surface treatment process for surgical drapes that is antistatic and has low lint shedding includes the following steps:

[0031] S1. Surgical drapes are treated with dielectric barrier discharge plasma.

[0032] S2. Apply an antistatic agent solution to the sheet treated in step S1 by padding or spraying, and react at 80~120 ℃ for 3~10 min.

[0033] S3. The capping agent solution is evenly sprayed onto the surface of the sheet treated in step S2 by ultrasonic atomization spraying; the capping agent solution contains 3~8 wt% low melting point polymer, 0.1~0.5 wt% auxiliary film-forming agent and solvent;

[0034] S4. The fabric treated in step S3 is subjected to high-pressure steam sterilization at 117-125 ℃ to melt the low-melting-point polymer and migrate to the fiber ends. After cooling, an antistatic, low-lint surgical fabric is obtained.

[0035] In some specific embodiments, in step S3, the low-melting-point polymer is one of polyethylene glycol (PEG) with a molecular weight of 1500-4000 Da or polycaprolactone (PCL) with a molecular weight of 2000-5000 Da; the auxiliary film-forming agent is hydroxypropyl methylcellulose (HPMC); and the solvent is a water / ethanol mixture with a volume ratio of 6-7:3-4.

[0036] In some specific embodiments, in step S3, the particle size of the atomized spray is controlled to be 5~20 μm, and the spraying amount is 1~3 g / m². 2 An auxiliary wind speed of 0.5~1 m / s.

[0037] In some specific embodiments, in step S1, the processing gas for plasma treatment is argon or an argon / oxygen mixture, with a volume ratio of argon / oxygen mixture of 90~95:5~10.

[0038] In some specific implementations, in step S1, the plasma treatment power is 50~150 W, the treatment time is 30~120 s, and the treatment distance is 5~20 mm.

[0039] In some specific embodiments, in step S2, the antistatic agent solution is an aqueous solution or an alcoholic aqueous solution of a permanent antistatic agent containing reactive groups, with a concentration of 5-15 wt%.

[0040] In some specific embodiments, the reactive group is one of epoxy group, isocyanate group or siloxane group; the permanent antistatic agent is selected from one of epoxy-modified polyether type antistatic agent, isocyanate-terminated polyether / polyester type antistatic prepolymer or organosiloxane containing quaternary ammonium salt group.

[0041] In some specific implementations, in step S2, the padding method is one dip and one roll with a roll-off rate of 70-90%; the spraying method has a pressure of 1-3 bar and a flow rate of 100-300 mL / min.

[0042] In some specific implementations, in step S4, the pressure of autoclaving is 0.1-0.2 MPa and the time is 8-15 min.

[0043] To further simplify and make the present invention achieve its objectives and effects, the present invention will be further illustrated in conjunction with the following specific embodiments and comparative examples, but the present invention is not limited to the scope of the embodiments described herein.

[0044] It should be noted that in the examples and comparative examples, the surgical drapes used medical-grade polypropylene (PP) spunbond-meltblown composite nonwoven fabric as the substrate, with a basis weight of 60 g / m². 2 Thickness 0.2 mm, fiber diameter 3-4 μm, porosity 85%, surface resistivity 5.1×10⁻⁶ 15Ω / sq; The raw materials for preparation are as follows: PEG: molecular weight 2800 Da, purity ≥99.9%, purchased from Jinan Xinke Chemical; PCL: molecular weight 4000 Da, purchased from Dongguan Baojia Plastics; HPMC: purity ≥98%, purchased from Hubei Langbowan Biomedical; Antistatic agent solution: aqueous solution of epoxy-modified polyether antistatic agent (polyethylene glycol diglycidyl ether derivative), purchased from Jinan Shiji Tongda Chemical. Example 1

[0045] A surface treatment process for surgical drapes that is antistatic and has low lint shedding includes the following steps:

[0046] S1. The surgical drape is treated with dielectric barrier discharge plasma. The treatment gas is an argon / oxygen mixture with a volume ratio of 95:5. The treatment power is 100 W, the treatment time is 60 s, and the treatment distance is 10 mm.

[0047] S2. Apply an antistatic agent solution to the sheet processed in step S1 using a padding method. The antistatic agent solution is a 10wt% aqueous solution of epoxy-modified polyether antistatic agent. One dip and one pad, with a padding rate of 80%, followed by reaction at 100 °C for 6 min.

[0048] S3. The capping agent solution is applied via ultrasonic atomization spraying at a particle size of 12 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the sheet after the S2 step treatment. The end-capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0049] S4. The surgical drape processed in step S3 is steam-sterilized at 121 °C and 0.15 MPa for 12 min to melt the PEG and migrate it to the fiber ends. After cooling, an antistatic, low-lint surgical drape is obtained. Example 2

[0050] This embodiment is basically the same as Example 1, except that the low-melting-point polymer raw material in the capping agent solution is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the capping agent solution with a particle size of 12 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the sheet after the S2 step treatment. The end-capping agent solution consisted of 5 wt% PCL, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 3

[0051] This embodiment is basically the same as Example 1, except that the concentration of the low-melting-point polymer in the capping agent solution is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the capping agent solution with a particle size of 12 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 3 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 4

[0052] This embodiment is basically the same as Example 1, except that the concentration of the low-melting-point polymer in the capping agent solution is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the capping agent solution with a particle size of 12 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 8 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 5

[0053] This embodiment is basically the same as Embodiment 1, except that the particle size of the ultrasonic atomization spray is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the sealing agent solution with a particle size of 5 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3. Example 6

[0054] This embodiment is basically the same as Embodiment 1, except that the particle size of the ultrasonic atomization spray is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the sealing agent solution with a particle size of 20 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0055] Comparative Example 1:

[0056] This comparative example is basically the same as Example 1, except that: no plasma, antistatic agent and end-capping agent treatment was performed. Specifically, steps S1, S2 and S3 were omitted, and only step S4 was used for high-pressure steam sterilization.

[0057] Comparative Example 2:

[0058] This comparative example is basically the same as Example 1, except that no end-capping agent treatment was performed, specifically, step S3 was omitted.

[0059] Comparative Example 3:

[0060] This comparative example is basically the same as Example 1, except that the concentration of the low-melting-point polymer in the capping agent solution is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the capping agent solution with a particle size of 12 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 2 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0061] Comparative Example 4:

[0062] This comparative example is basically the same as Example 1, except that the concentration of the low-melting-point polymer in the capping agent solution is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the capping agent solution with a particle size of 12 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 10 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0063] Comparative Example 5:

[0064] This comparative example is basically the same as Example 1, except that the particle size of the ultrasonic atomization spray is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the sealing agent solution with a particle size of 3 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0065] Comparative Example 6:

[0066] This comparative example is basically the same as Example 1, except that the particle size of the ultrasonic atomization spray is different. Specifically, step S3 involves ultrasonic atomization spraying to apply the sealing agent solution with a particle size of 25 μm and a concentration of 2 g / m³. 2 The coating amount was 0.8 m / s, and the auxiliary wind speed was 0.8 m / s. The coating was evenly sprayed onto the surface of the single layer after the S2 step treatment. The end-capping agent solution consisted of 5 wt% PEG, 0.3 wt% HPMC and a water / ethanol mixed solvent with a volume ratio of 7:3.

[0067] Comparative Example 7:

[0068] This comparative example is basically the same as Example 1, except that: no plasma treatment was performed, specifically, step S1 was omitted.

[0069] Comparative Example 8:

[0070] This comparative example is basically the same as Example 1, except that: high-pressure steam sterilization is replaced by hot air curing, and step S4 is specifically: the sheet processed in step S3 is cured with hot air at 121 °C for 12 min, and after cooling, an antistatic, low-lint surgical sheet is obtained.

[0071] Performance testing: The surgical sheets obtained in Examples 1-6 and Comparative Examples 1-8 were subjected to antistatic and anti-linting performance tests in sequence. The results are shown in Table 1.

[0072] Antistatic testing: A high-resistivity meter (model EST121) was used with a three-electrode method (electrode spacing 5 cm). A DC voltage of 100 V was applied to the sample, and the surface resistivity was recorded after standing for 1 min. Five different areas of each sample were tested, and the average value was taken as the resistivity.

[0073] Anti-fluffing: Using a Martindale abrasion tester (500 g load), the surgical drape was fixed on the friction table and rubbed 5000 times at a frequency of 120 times / min. The friction products were collected and transferred to a 1m... 3 Inside the sealed test chamber, a laser particle counter with a range of 0.5~10 μm was used to collect air samples from the chamber at a flow rate of 1 L / min for 5 min, and the total number of particles ≥50 μm was recorded. Each sample was tested in parallel 3 times and the average value was taken.

[0074] Table 1: Performance test results of surgical draping in Examples 1-6 and Comparative Examples 1-8

[0075]

[0076] As shown in Table 1:

[0077] A comparison between Example 1 and Comparative Example 1 reveals that: Comparative Example 1, lacking an antistatic layer and end-capping structure, exhibits low surface energy of polypropylene fibers, resulting in a lack of active sites that prevent charge dissipation and an initial resistivity as high as 5.0 × 10⁻⁶. 15 Ω / sq, and the fiber ends are uncoated, resulting in a large number of breakages under frictional stress, with the number of lint particles reaching 253 particles / dm. 2 This confirms that untreated sheets pose a serious risk of electrostatic contamination and lint shedding in the surgical environment.

[0078] A comparison between Example 1 and Comparative Example 2 reveals that, despite the antistatic layer maintaining a low resistivity through covalent grafting after the lack of end-capping agent treatment, the fiber ends are exposed to mechanical friction, causing the β bonds of the polypropylene molecular chains to break easily during repeated folding, resulting in a surge in lint shedding to 217 particles / dm³. 2 After treatment in Example 1, the number of lint particles was only 15 particles / dm². 2 The microsphere-like mechanical locks formed by end-capping and coagulation can effectively eliminate the source of lint shedding. Simultaneously, due to the repeating ether bonds in the PEG molecular chain, hydrogen bonds or van der Waals forces can form with active free radicals on the fiber surface after plasma activation, widening the charge dissipation channel and increasing the rate of static charge dissipation. Even after treatment without the end-capping agent, the resistivity also increases to 6.2 × 10⁻⁶. 9 Ω / sq.

[0079] A comparison of Examples 1 and 3-4 with Comparative Examples 3-4 reveals that when the concentration of the low-melting-point polymer in the capping agent is in the range of 3-8 wt%, PEG forms a dynamic melt during high-pressure steam sterilization. Its ether bonds form hydrogen bonds with the hydroxyl groups on the fiber surface, guiding the molecular chains to migrate along the fiber axis to the ends. Each PEG molecule contains approximately 68 ether bond units, which, through van der Waals forces, entangle the fiber breakage points. After cooling, a microsphere anchoring structure is formed, thereby stabilizing the number of lint particles at 15-37 particles / dm². 2 ;

[0080] When the concentration of low-melting-point polymer in the end-capping agent of Comparative Example 3 decreased to 2 wt%, the PEG chain segment density was insufficient and could not completely cover the fiber end breakage points, resulting in an increase in lint shedding to 104 particles / dm². 2 In contrast, in Comparative Example 4, the concentration of the low-melting-point polymer in the capping agent increased to 10 wt%. The high concentration of PEG resulted in excessive film formation, and cracks formed after solvent evaporation, leading to an increase in the number of lint particles to 61 particles / dm². 2 Furthermore, the film layer hinders the electrostatic charge conduction path, causing the resistivity to rise to 2.1 × 10⁻⁶. 9 Ω / sq.

[0081] A comparison of Examples 1 and 5-6 with Comparative Examples 5-6 reveals that: a suitable atomized particle size allows penetration into the fiber gaps without reaching the interior of the monofilament, ensuring that PEG migrates only on the surface and uniformly covers the fiber surface; when the atomized spray particle size is reduced to 3 μm, the excessively small droplets penetrate deep into the fiber interior. During high-pressure steam sterilization, PEG preferentially fills the pores rather than migrates to the ends, resulting in a decrease in coating efficiency and an increase in lint shedding to 89 particles / dm. 2 When the atomized spray particle size increases to 25 μm, excessively large droplets accumulate on the surface to form a film, reducing droplet penetration and hindering subsequent steam sterilization penetration. Insufficient swelling of HPMC leads to deviation of the PEG migration path and a decrease in end-capture rate.

[0082] A comparison between Example 1 and Comparative Example 7 shows that without plasma treatment, the polypropylene fiber surface contains only inert methyl groups, which cannot undergo a ring-opening reaction with the epoxy groups of the antistatic agent. The antistatic agent adheres to the fiber surface only through physical adsorption, resulting in a resistivity increase to 8.2 × 10⁻⁶. 10 Ω / sq, and the unactivated fiber surface hinders PEG hydrogen bonding, resulting in failure of lint control.

[0083] A comparison between Example 1 and Comparative Example 8 shows that after replacing high-pressure steam sterilization with hot air curing, the number of lint particles decreased from 15 particles / dm³. 2 Increased to 63 particles / dm 2 In a steam environment, HPMC, the auxiliary film-forming agent, swells instantly upon contact with water vapor, guiding PEG / PCL to migrate along the fiber surface via capillary action. However, hot air curing causes the solvent to evaporate rapidly, restricting the movement of polymer chain segments. This results in a discontinuous coating that can only be formed on the fiber surface, making it difficult to effectively wrap the end breakage points.

[0084] The above description is based on the preferred embodiments of the present invention. It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the embodiments should be considered exemplary and non-limiting in all respects. The scope of the invention is defined by the appended claims rather than the foregoing description, and all variations falling within the meaning and scope of equivalents of the claims are intended to be included within the present invention. No reference numerals in the claims should be construed as limiting the scope of the claims.

[0085] Furthermore, it should be understood that although this specification describes embodiments, not every embodiment contains only one independent technical solution. This narrative style is merely for clarity. Those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.

Claims

1. A surface treatment process for surgical drapes that is antistatic and has low lint shedding, characterized in that, Includes the following steps: S1. Surgical drapes are treated with dielectric barrier discharge plasma. S2. Apply an antistatic agent solution to the sheet treated in step S1 by padding or spraying, and react at 80~120 ℃ for 3~10 min. S3. The capping agent solution is uniformly sprayed onto the surface of the sheet treated in step S2 by ultrasonic atomization spraying; the capping agent solution contains 3~8 wt% of low melting point polymer, 0.1~0.5 wt% of auxiliary film-forming agent and solvent; S4. The surgical drape processed in step S3 is subjected to high-pressure steam sterilization at 117-125 ℃ to melt the low-melting-point polymer and migrate to the fiber ends. After cooling, an antistatic and low-lint surgical drape is obtained. In step S2, the antistatic agent solution is an aqueous solution or an alcoholic aqueous solution of a permanent antistatic agent containing reactive groups, wherein the reactive groups are one of epoxy groups, isocyanate groups, or siloxane groups. In step S3, the low-melting-point polymer is either polyethylene glycol with a molecular weight of 1500-4000 Da or polycaprolactone with a molecular weight of 2000-5000 Da; the particle size of the atomized spray is controlled to be 5-20 μm.

2. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S3, the auxiliary film-forming agent is hydroxypropyl methylcellulose; the solvent is a water / ethanol mixture with a volume ratio of 6~7:3~4.

3. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S3, the spraying amount of the atomized coating is 1~3 g / m³. 2 An auxiliary wind speed of 0.5~1 m / s.

4. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S1, the processing gas for plasma treatment is argon or an argon / oxygen mixture, wherein the volume ratio of the argon / oxygen mixture is 90~95:5~10.

5. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S1, the plasma treatment power is 50~150 W, the treatment time is 30~120 s, and the treatment distance is 5~20 mm.

6. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S2, the concentration of the antistatic agent solution is 5-15 wt%.

7. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: The permanent antistatic agent is selected from one of the following: epoxy-modified polyether antistatic agent, isocyanate-terminated polyether / polyester antistatic prepolymer, or organosiloxane containing quaternary ammonium salt groups.

8. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S2, the padding method is one dip and one roll, with a roll-up rate of 70-90%; the spraying method has a pressure of 1-3 bar and a flow rate of 100-300 mL / min.

9. The surface treatment process for antistatic and low-lint surgical drapes according to claim 1, characterized in that: In step S4, the pressure of the high-pressure steam sterilization is 0.1-0.2 MPa, and the time is 8-15 min.

10. A surgical drape with antistatic and low lint shedding, characterized in that: Obtained by any one of the surface treatment processes according to claims 1-9.

Images